In this white paper Biomatters President Brett Ammundsen (PhD) discusses how a scalable cloud computing data platform that combines data management with scientific and data analysis workflows can drive competitive advantage and ultimately ensure the availability of more effective and safe antibody drugs for patients.
Download the whitepaper to discover:
- Technological barriers to effective antibody discovery and how they can be addressed
- How to reduce time to market, improve the ability to identify promising candidates and ‘fail early’ in the drug discovery phase
- Why better data integration and collaboration minimizes the chance of missing quality antibody candidates